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ABSTRACT  22 
Pseudomonas aeruginosa plays a major role in many chronic infections.  Its ability to readily 23 
form biofilms contributes to its success as an opportunistic pathogen and its 24 
resistance/tolerance to antimicrobial/antibiotic therapy.  A low molecular weight alginate 25 
oligomer (OligoG CF-5/20), derived from marine algae, has previously been shown to impair 26 
motility in P. aeruginosa biofilms and disrupt pseudomonal biofilm assembly.  As these 27 
bacterial phenotypes are regulated by quorum sensing (QS), we hypothesized that OligoG 28 
CF-5/20 may induce alterations in QS signalling in P. aeruginosa.  QS regulation was studied 29 
using Chromobacterium violaceum CV026 biosensor assays that showed a significant 30 
reduction in acyl homoserine lactone (AHL) production following OligoG CF-5/20 treatment 31 
(≥2%; P<0.05).  This effect was confirmed by liquid chromatography/mass spectrometry 32 
(LC/MS) analysis of C4-AHL and 3-oxo-C12-AHL production (≥2%; P<0.05).  Moreover, 33 
quantitative PCR (qPCR) showed that reduced expression of both the las and rhl systems 34 
was induced following 24 h treatment with OligoG CF-5/20 (≥0.2%; P<0.05).  Circular 35 
dichroism (CD) spectroscopy indicated that these alterations were not due to steric 36 
interaction between the AHL and OligoG CF-5/20.  Confocal laser scanning microscopy and 37 
COMSTAT image analysis demonstrated that OligoG CF-5/20 treated biofilms had a dose-38 
dependent decrease in biomass which was associated with inhibition of eDNA synthesis 39 
(≥0.5%; P<0.05).  These changes correlated with alterations in extracellular production of 40 
the pseudomonal virulence factors pyocyanin, rhamnolipids, elastase and total protease 41 
(P<0.05).  The ability of OligoG CF-5/20 to modify QS signalling in P. aeruginosa PAO1 which 42 
may influence critical downstream functions, such as virulence factor production and biofilm 43 
formation.     44 
  45 
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INTRODUCTION  46 
Pseudomonas aeruginosa is an opportunistic and nosocomial human pathogen, which can 47 
cause extensive tissue damage through the production of virulence factors and toxins e.g. 48 
pyocyanin and proteases (1).  The dynamic genome of P. aeruginosa is highly adaptable, 49 
enabling it to adjust to a wide range of environmental conditions (2, 3).  This versatility 50 
allows it to colonise diverse physiological niches including the respiratory tract, genito-51 
urinary tract and wounds.   52 
The sodium alginate oligomer OligoG CF-5/20, produced from the brown seaweed 53 
Laminaria hyperborea, has been shown to potentiate (enhance) antimicrobial efficacy, 54 
perturb multidrug resistant bacteria (4-7) and inhibit biofilm formation in a broad range of 55 
organisms (8).  Furthermore, it has also previously been shown to inhibit swarming and 56 
“twitching” motility, exhibiting a significant effect on bacterial flagella- and pilus-mediated 57 
chemotaxis (4, 5).  Although OligoG CF-5/20 is known to have cation-chelating properties, 58 
the precise mechanism of action in mediating this diverse range of effects remains unclear.   59 
Quorum sensing (QS) is a cell density-dependent communication system between 60 
local populations of bacterial cells, regulating and coordinating their gene expression using 61 
diffusible signalling molecules (9, 10).  In Gram-negative pathogens (in particular P. 62 
aeruginosa), QS is regulated by acylated homoserine lactones (AHLs) produced by a 63 
transcriptional regulator based on the LuxR/LuxI-type QS system that was first characterized 64 
in Vibrio fischeri (11).  The regulation of QS in Pseudomonas spp. is both subtle and complex 65 
(12) (Fig 1).  P. aeruginosa has four QS systems, two acyl-homoserine lactone (AHL)- and one 66 
2-heptyl-3-hydroxy-4-quinolone- mediated system known as the Pseudomonas quinolone 67 
signal (PQS) system and the more recently identified integrated QS system (IQS) (13).  The 68 
AHL systems in P. aeruginosa are known as the lasI-lasR and rhlI-rhlR systems and the 69 
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transcriptional regulators LasR and RhlR regulate production of the signalling molecules 70 
(autoinducers) N-(3-oxododecanoyl)-L-AHL (3-oxo-C12-AHL) and N-butyryl-L-AHL (C4-AHL) 71 
respectively.  The QS system in P. aeruginosa is regulated by an inter-linked, hierarchical 72 
mechanism where lasR/3-oxo-C12-AHL induces expression of lasI, as well as rhlR/rhlI and 73 
the PQS system.  Disruption of the IQS signal can effectively paralyze the PQS and rhl QS 74 
systems (14).  A number of additional regulators of this QS system exist, at both 75 
transcriptional and post-transcriptional levels, including the global activator GacA and 76 
regulator Vfr (13).  In addition, QS also regulates key cellular processes such as promotion of 77 
eDNA release, RNA transcription and translation, cellular division and amino acid synthesis.  78 
Global gene expression analysis of the QS systems in P. aeruginosa has shown that 6-79 
10% of the genome is regulated through the las and rhl systems (12, 15).  QS plays a role in 80 
swarming motility, biofilm development and expression of antibiotic efflux pumps (16) as 81 
well as virulence factor production.  P. aeruginosa QS-activated virulence factors include 82 
proteases e.g. elastase, pyocyanin, lectins, rhamnolipids, and toxins.  Such virulence factors 83 
can affect biofilm formation and maintenance, as well as swarming motility.  Their 84 
regulation is complex, with numerous intrinsic and environmental factors involved such as 85 
cell-number, composition of the extracellular polymeric substance (EPS), matrix density and 86 
oxygen availability.  However, the production of pyocyanin, proteases and rhamnolipids 87 
reflects optimal QS signalling (17).  Pyocyanin is a blue secondary metabolite produced by P. 88 
aeruginosa evident in the sputum of infected cystic fibrosis patients (18).  As a zwitter ion, 89 
at a physiological pH, it can readily penetrate biological membranes, inducing host cell 90 
necrosis and inflammation, both directly (e.g. IL-8) and indirectly via cellular damage (19).  91 
Importantly, in the context of biofilm persistence in vivo, pyocyanin induces the deposition 92 
of extracellular DNA (eDNA) which is a major component of biofilm EPS, being essential for 93 
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biofilm formation and stability (20).  Production of both pyocyanin and eDNA is mediated by 94 
AHL and PQS molecules, as well as by flagella and type IV pili (21, 22).   95 
The regulation of QS in P. aeruginosa is sensitive to, and modulated by, growth and 96 
environmental conditions, which impact significantly on the timing of lasI, lasR, rhlI and rhlR 97 
expression (9, 23).  The complexity of this QS system in P. aeruginosa is thought to be one of 98 
the main factors responsible for its selective adaption and environmental versatility (24).  99 
The QS system also affords selective “fitness” advantages in human disease.  For example, 100 
QS signalling molecules produced by P. aeruginosa are also recognised by Burkolderia 101 
cepacia, resulting in synergistic interactions in mixed-species biofilms (25), thereby 102 
potentially increasing the virulence of both species in the cystic fibrosis lung.  Moreover, the 103 
expression of AHL and PQS molecules has been shown to affect the mammalian host-104 
pathogen response (26) with 3-oxo-C12-AHL and PQS having anti-inflammatory and pro-105 
apoptotic effects on murine fibroblasts and human lung epithelial cells at concentrations 106 
<10 μM (27).  107 
Rhamnolipids are bacterial glycolipid surfactants, composed of a rhamnose glycosyl 108 
head and a 3-(hydroxyalkanoyloxy) alkanoic acid fatty acid tail.  Rhamnolipid expression 109 
plays a crucial role in microbial motility, hydrophobic uptake and biofilm formation on host 110 
surfaces.  Proteases (including the zinc-dependent metalloproteinase elastase) also play an 111 
important role in the pathogenicity of Pseudomonas spp. facilitating invasion and 112 
destruction of host tissue (28).  Rhamnolipid production is regulated by the P. aeruginosa 113 
quorum sensing regulator, rhlR, whilst elastase and protease activities are regulated by the 114 
lasIR system.   115 
QS inhibitors that impede QS pathways in microorganisms are an attractive target 116 
for antimicrobial therapy development.  We hypothesized that the antibiotic susceptibility, 117 
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motility and biofilm-assembly modifications induced in P. aeruginosa by OligoG CF-5/20 118 
might relate to alterations in the regulation of lasI-lasR and rhlI-rhlR and studied this in vitro. 119 
 120 
 121 
RESULTS  122 
OligoG CF-5/20 inhibits growth of P. aeruginosa PAO1 and reduces violaceum 123 
induction and inhibition of the Chromobacterium violaceum biosensor CV026.  The effect 124 
of OligoG CF-5/20 on the growth of P. aeruginosa PAO1 was examined using growth curves.  125 
OligoG CF-5/20 at concentrations of ≥2% was found to significantly reduce the growth P. 126 
aeruginosa PAO1 (Minimum significant difference, MSD=0.154; P<0.01; Fig 2A).  This growth 127 
curve data was used to determine the time-points (12, 18, 24 and 30 h) employed in the 128 
subsequent time-course study.  129 
A time-course study was undertaken using induction or inhibition of violaceum in the 130 
Chromobacterium violaceum biosensor strain CV026 as an indicator of QS signalling (C4-AHL 131 
and 3-oxo-C12-AHL respectively), following treatment with OligoG CF-5/20 (Fig 2B, 2C and 132 
2D).  Untreated controls showed distinct differences in P. aeruginosa PAO1 AHL production 133 
with time, which were maximal at 18 h for C4-AHL induction and 24 h for 3-oxo-C12-AHL 134 
inhibition.  OligoG CF-5/20 treated samples showed a reduction in C4-AHL, particularly at 18 135 
and 24 h which was significant from 0.2% OligoG CF-5/20 and at 30 h from 2% (Fig 2B and 136 
2C).  Measurement of zones of clearing indicated that OligoG CF-5/20 had less of an effect 137 
on 3-oxo-C12-AHL inhibition when compared to C4-AHL induction (zone of coloration).  138 
Violaceum inhibition was significantly reduced at the 24 h time point, at all OligoG CF-5/20 139 
concentrations, in comparison to the control (P<0.05; Fig 2B and 2D). 140 
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Homoserine lactones C4-AHL and 3-oxo-C12-AHL can be detected using LC/Mass 141 
Spectrometry.  For a more accurate determination of AHL concentrations, preliminary 142 
analysis of the AHLs, C4-AHL (Fig 3A) and 3-oxo-C12-AHL (Fig 3B) using LC/MS (Fig 3C) was 143 
undertaken from an initial time course following PAO1 growth at 18, 24 and 30 h.  LC/MS 144 
demonstrated a time-dependent decrease in C4-AHL (Fig 3D) which was significantly 145 
different at 30 h (P<0.05).  Conversely, levels of 3-oxo-C12-AHL were considerably lower (up 146 
to 6-fold) and did not demonstrate time-dependent decreases.  147 
LC/Mass Spectrometry shows time-dependent decreases in AHL production following 148 
OligoG CF-5/20 treatment.  A subsequent time-course of OligoG CF-5/20-treated PAO1 149 
(grown at 12, 18, 24 and 30 h) demonstrated significant reductions in C4-AHL production at 150 
all time-points ≥2 % OligoG (Fig 4A), the exception being 18 h at 2% which was not 151 
significant.  A similar significant reduction was seen for 3-oxo-C12-AHL (Fig 4B; P<0.05) in 152 
comparison to the untreated control (except for 18 and 24 h at 2%), although much lower 153 
overall levels were detected (up to 29.5 mg/L) compared to C4-AHL (up to 102.3 mg/L) (Fig 154 
4).  155 
OligoG CF-5/20 reduces extracellular virulence factor production in P. aeruginosa 156 
PAO1.  As the biosensor analysis showed that OligoG CF-5/20 affected bacterial signalling, 157 
the production of virulence factors, regulated in P. aeruginosa PAO1 by quorum sensing, 158 
was investigated.  OligoG CF-5/20 (≥ 0.2%) significantly reduced the amount of pyocyanin at 159 
all time points ≥18 h (Fig 5A; P<0.05).  However, for rhamnolipid production a significant 160 
reduction was only observed at 18 h (for all OligoG CF-5/20 concentrations tested) or 24 h 161 
(at ≥2% OligoG CF-5/20; P<0.05) with no significant change seen at either 12 or 30 h (Fig 162 
5B).  In contrast, a significant reduction in total protease (Fig 5C) and elastase (Fig 5D) 163 
production was seen at ≥0.2% OligoG CF-5/20 and then only at the 24 h time point (P<0.05).   164 
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OligoG CF-5/20 reduces expression of quorum sensing genes.  Phenotypic studies were 165 
confirmed by genotypic analysis using qPCR.  Temporal expression of QS genes following 166 
OligoG CF-5/20 treatment was observed (Fig 6).  Significant reductions in expression of lasI, 167 
rhlI and rhlR at 12 h (Fig 6A), lasI, lasR and rhlR at 18 h (Fig 6B) and rhlR at 24 h (Fig 6B and C 168 
respectively; p<0.05) were evident, which for lasI, rhlI and rhlR at 12 h and lasR at 18 h, 169 
were significant for all three concentrations of OligoG tested.  No significant effect of OligoG 170 
CF-5/20 on AHL expression was detected by qPCR at the 30 h time point (Fig 6D). 171 
CLSM shows that OligoG CF-5/20 reduces production of eDNA and behaves similarly 172 
to QS inhibitors against biofilms of P. aeruginosa PAO1.  CLSM imaging of TOTO-1 nucleic 173 
acid-stained 24 h biofilms demonstrated that OligoG CF-5/20 (≥ 0.5% ) induced a significant 174 
decrease in eDNA production after treatment (P>0.05) (Fig 7 and 8).  This was evident in 175 
biofilms grown in the presence of OligoG (biofilm formation studies) and for 24 h biofilms 176 
subsequently treated with OligoG for 24 h (biofilm disruption studies).  Although the CLSM 177 
imaging did not appear to show a dose-dependent decrease in eDNA production (Fig 7).  A 178 
dose-dependent decrease was, however, evident at ≥2% OligoG in direct analysis of treated 179 
biofilm samples (Fig 8). 180 
The structural alterations induced in biofilms by OligoG CF-5/20 were compared to the 181 
effects of the QS inhibitors, 2(5H)-furanone and N-decanoyl cyclopentylamide (C10-CPA) 182 
(29, 30) using LIVE/DEAD staining (S1A Fig) showing that the effects of OligoG resembled the 183 
inhibition induced by the other AHL-dependent quorum sensing inhibitors tested (S1B and 184 
S1C Fig).  185 
Circular dichroism showed that OligoG CF-5/20 does not interact directly with AHLs.  186 
Circular dichroism (CD) spectroscopy rapidly determines protein and polypeptide secondary 187 
structure, and has previously been shown to give excellent comparability to 1H NMR 188 
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spectroscopy in determining alginate M/G residue ratios (31).  CD was used here to confirm 189 
that the effects of OligoG CF-5/20 were not due to simple physical interaction with the AHL 190 
molecules.  The CD signal of OligoG CF-5/20 titrated with C4-AHL or 3-oxo-C12-AHL showed 191 
no substantial change (S2 Fig).  The minima of the spectra around 210 nm, revealing the 192 
orientation of the alginate carboxy groups and thus directly indicative of the conformation 193 
of OligoG CF-5/20 (32), appeared unaffected by either of the two AHLs.  The ellipticities 194 
recorded at 208 nm (after addition of AHLs at their maximum concentrations over ~1h) 195 
suggested that kinetic effects were not responsible for the absence a signal (insets in S2 Fig). 196 
 197 
 198 
DISCUSSION  199 
This study confirms that OligoG CF-5/20 affects global regulatory QS signalling in P. 200 
aeruginosa PAO1 as was hypothesised following the original observations on bacterial 201 
motility (4, 7).  The biosensor strain C. violaceum CV026 demonstrated that OligoG CF-5/20 202 
reduced C4-AHL and 3-oxo-C12-AHL production in P. aeruginosa PAO1, (as seen by QS 203 
induction and inhibition respectively) in a time- and dose-dependent manner.  This was 204 
further confirmed by LC/MS and qPCR, and that OligoG CF-5/20 also had a significant effect 205 
on the production of other virulence factors such as pyocyanin, rhamnolipid, total protease, 206 
and elastase.  The dose-dependent nature of the observed inhibition suggested that OligoG 207 
does not simply act as an AHL receptor antagonist by binding to the receptor, thereby 208 
effectively “blocking” all AHL binding.  Furthermore, the CD analysis excluded the possibility 209 
that the observed alterations in QS signalling molecules and virulence factor expression 210 
were the result of simple, steric interactions between the oligosaccharide and the AHL 211 
signalling molecules in the biofilm system. 212 
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The LC/MS data demonstrated the complex, time-dependent nature of virulence factor 213 
production by P. aeruginosa with optimal (maximum) production of both AHLs (C4-AHL and 214 
3-oxo-C12-AHL) at 12 h (equivalent to late exponential/early stationary growth phase).  215 
These findings are in keeping with previous studies, which showed that whilst AHL 216 
production peaks during exponential growth, C4-AHL levels decrease as stationary phase is 217 
attained (12).  The finding here, that 3-oxo-C12-AHL levels remained relatively constant if 218 
the medium was sufficiently buffered to avoid alkali-mediated lactonolysis, is consistent 219 
with those of Yates et al (33).   220 
Las and Rhl are regulated by the LuxR family of transcriptional regulators (lasR and 221 
RhlR), making their expression extremely sensitive to environmental conditions e.g. hypoxia, 222 
pH and hydrodynamic shear (which are important in biofilm infections).  AHL production has 223 
been shown to vary significantly under different environmental growth conditions, 224 
especially under nutrient-limitation, with higher AHL expression observed in minimal or 225 
diluted media, when compared to nutrient media (9).  In addition, both las and rhl were 226 
expressed earlier (in early to mid-log phase) in nutrient-limited media compared to early 227 
stationary phase in nutrient media.  Interestingly, these phenomena were unrelated to cell-228 
density, which is usually considered a pre-requisite for QS expression.  Comparing 46 229 
different experimental conditions, Duan and Surette (9) showed that the individual 230 
dominance of the las and rhl system reflected environmental conditions.  LasR mutants are 231 
commonly found in both clinical and environmental isolates, indicating autonomous 232 
regulation of these integrated systems (34, 35).  Transcription of Las and Rhl may also occur 233 
independently, permitting further “fine-tuning” of each system in vivo.  This may, in part, 234 
explain the independent (and distinct) responses to OligoG CF-5/20 treatment observed in 235 
C4-AHL and 3-oxo-C12-AHL production in the time-course experiments. 236 
11 
 
Swarming is a complex form of motility, and is consequently influenced by a large 237 
number of different genes.  Rhamnolipids are known to modulate the intricate swarming 238 
motility patterns of P. aeruginosa (36).  Therefore, it was perhaps unsurprising that, as 239 
OligoG CF-5/20 was previously shown to affect swarming motility of Proteus and P. 240 
aeruginosa (4, 7 respectively), that rhamnolipid production should also be affected by 241 
OligoG CF-5/20.  Importantly, QS regulation of rhamnolipids and swarming motility 242 
contribute to P. aeruginosa biofilm dispersal, and therefore help to explain the dramatic 243 
effect of OligoG CF-5/20 on both biofilm formation and disruption of established biofilms 244 
previously described (4, 7).  In support of this notion, a range of mini-Tn5 insertion, 245 
“swarming-negative” P. aeruginosa mutants exhibited impaired biofilm formation (37), 246 
confirming the link between both phenotypes.  The finding here, of more significant 247 
inhibition of pyocyanin and rhamnolipid production by OligoG CF-5/20 (when compared to 248 
the effects on elastase and total protease production) may relate to differential expression 249 
of the different QS pathways.  The three most characterised QS signalling systems in P. 250 
aeruginosa are believed to be sequentially activated in “nutrient-rich” media, with LasR 251 
sitting at the top of the temporal cascade, and AHLs (las and rhl) being released in early- and 252 
PQS in late-exponential phases of growth (38).  253 
Las and Rhl control both biofilm formation and expression of virulence factors in P. 254 
aeruginosa (11).  The LasR–3-oxo-C12-AHL complex activates transcription of target genes 255 
including those encoding virulence factors such as elastase, proteases, and exotoxin.  In 256 
contrast, RhlR–C4-AHL activates target genes, including those encoding elastase, proteases, 257 
pyocyanin, and siderophores (39).  There appears to be a considerable overlap in the 258 
virulence factors these regulons control (9).  The finding that the inhibition of 259 
pyocyanin/rhamnolipid production was more evident throughout the time-course of the 260 
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experiment than that of protease and elastase, may be a reflection of OligoG differentially 261 
affecting the Rhl QS system, to a greater extent than the Las system.   262 
The intrinsically high levels of antimicrobial resistance typically seen in P. aeruginosa 263 
are due to its low permeability and multidrug efflux systems, four of which contribute 264 
significantly to innate antibiotic resistance.  Khan et al. (4) demonstrated that OligoG CF-265 
5/20 increased potentiation of antibiotics against MDR bacteria (up to 128 fold).  The 266 
authors established that this did not relate simply to permeabilisation of the pseudomonal 267 
lipopolysaccharide cell-wall or targeting of the multi-drug efflux pump MexAB-OrpM, 268 
suggesting that the QS inhibition observed here with OligoG CF-5/20, involves a mechanism 269 
other than inhibition of AHL efflux pumps in P. aeruginosa.  Instead, the OligoG CF-5/20-270 
induced reduction in AHL production more likely reflects an effect further “upstream” e.g. 271 
on bacterial two-component system (TCS) signal transduction pathways (40) by which 272 
means bacteria are able to detect and produce a response to environmental changes.   273 
TCSs are comprised of an inner membrane-bound “sensor” generally a histidine kinase 274 
(which detects environmental stimuli) and a response regulator (which modulates the 275 
response).  There are many TCSs in P. aeruginosa, and these are recognized to play a role in 276 
regulating bacterial virulence, biofilm formation and antibiotic susceptibility; factors known 277 
to be influenced by OligoG CF-5/20, although the precise links between TCSs and QS are still 278 
poorly understood (41).  At least three TCSs (BfiSR, MifR and BfmSR) are thought to be 279 
involved in the activation of biofilm formation (42).  The recently-published 280 
BfmS/BfmR/RhlR TCS has been shown to be key to regulation of the rhl QS pathway in P. 281 
aeruginosa (43) modulating expression of biofilm formation and virulence.  Interestingly, 282 
deletion of the sensor gene BfmS was shown to cause inhibition of the rhl QS system, with 283 
BfmR playing a central role in biofilm maturation.  In addition, it has also recently been 284 
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suggested that BfmRS is involved the development of virulence during bacterial adaptation 285 
to the CF lung (43, 44).  Interestingly, AlgR (another key Pseudomonas aeruginosa 286 
transcriptional response regulator) also appears to play an essential role in bacterial 287 
virulence and motility (45). 288 
The chemical composition of the EPS represents a formidable “barrier” to diffusion and 289 
contributes to resistance to antibiotic and antimicrobial therapy (46).  The physical 290 
disruption of the biofilm structure and alterations in eDNA distribution within the 291 
pseudomonal biofilms (induced by OligoG) was, perhaps, unsurprising as QS and pyocyanin 292 
have an important regulatory role in eDNA synthesis.  Pyocyanin induces eDNA release, with 293 
biofilms formed by QS mutants known to possess reduced eDNA compared to wild-type 294 
biofilms and to be more susceptible to chemical disruption (21, 47).  Our results further 295 
confirm these findings, where OligoG treatment of P. aeruginosa PAO1 resulted in 296 
significant decreases in pyocyanin and eDNA production  297 
Virulence-targeted anti-bacterials, which effectively ‘disarm’ pathogenic bacteria, have 298 
received considerable attention (48) although many have proved to be short-lived due to 299 
issues with toxicity and the acquisition of bacterial resistance.  Resistance to furanone in P. 300 
aeruginosa can be selected for in vitro, as well as being found in clinical isolates (49).  In 301 
contrast to many of the previously described therapeutic modalities, OligoG, which targets 302 
bacterial virulence as a QS antagonist, shows considerable promise.  Phase I and Phase IIa 303 
human studies failed to demonstrate toxicity.  Moreover, extended in vitro serial passage in 304 
the presence of OligoG, has failed to demonstrate the acquisition of bacterial resistance (4).   305 
As QS inhibitors target specific pathogenicity traits such as virulence determinants, 306 
there has been considerable interest in their use as use as novel anti-infective therapies (50) 307 
both by screening for novel compounds (51) and by targeted synthesis of new ligands (52).  308 
14 
 
Similar to OligoG, the QS inhibitors, furanone and C10-CPA have previously been shown to 309 
impede AHL-mediated QS in P. aeruginosa leading to an altered biofilm architecture, 310 
reduced virulence factor production, as well as enhanced bacterial detachment and 311 
antibiotic susceptibility (53, 30 respectively).  Predictably, the QS inhibition effects seen with 312 
OligoG appear to more closely resemble those of the C10-CPA tested here, interfering as it 313 
does with both the las and rhl QS systems, unlike furanone, which was predominantly found 314 
to perturb the las system.  The dose-response effects and effects on bacterial growth 315 
observed in this study suggest that although OligoG CF-5/20 does not act as a true QS 316 
inhibitor, it does act as a QS antagonist, affecting signalling pathways in P. aeruginosa, with 317 
expression of Las and Rhl QS pathways altered in a dose-dependent manner following 318 
OligoG CF-/20 treatment.  This also proposes a mechanistic rationale for the previously- 319 
described anti-biofilm properties of this novel antimicrobial agent that is currently in human 320 
clinical trials. 321 
 322 
 323 
MATERIALS AND METHODS 324 
Alginate oligosaccharides.  The low molecular weight alginate oligosaccharide, OligoG 325 
CF-5/20 (Mn = 2800) used in the study was prepared, purified and characterized as 326 
previously described (4).   327 
Growth curves.  Overnight cultures of P. aeruginosa PAO1 grown in tryptone soya broth 328 
at 37OC, 120 rpm were diluted (1:100) in Mueller-Hinton (MH) broth ± OligoG CF-5/20 (0.2%, 329 
2% and 10%).  The growth of P. aeruginosa PAO1 was monitored over 48 h, aerobically at 330 
37OC. Absorbance (OD600) values taken every hour in a in a FLUOstar Optima plate reader 331 
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(BMG LABTECH).  A one-way ANOVA using Tukey-Kramer post-test and the minimum 332 
significant difference generated.  333 
Chromobacterium violaceum CV026 biosensor strain.  C. violaceum CV026 is unable to 334 
produce the purple pigment violacein without an external source of AHLs; therefore, 335 
violacein production is induced by AHLs that are C4-C8 in length, whereas inhibition of 336 
violacein production can also occur using AHLs of a longer carbon chain length (C10-C14). 337 
Both P. aeruginosa AHLs can, therefore, be detected using the C. violaceum CV026 strain: 338 
C4-AHL by induction of violacein production, and 3-oxo-C12-AHL by inhibition.  339 
Acyl-homoserine lactone (AHL) extraction.  Cell free supernatants were collected and 340 
equivalent volumes of ethyl acetate (acidified by supplementing with 0.5% formic acid) 341 
added.  Following mixing for 30 s, the phases were allowed to separate and the top layer 342 
collected, this was repeated three times.  The combined ethyl acetate fractions were 343 
evaporated and the precipitate was resuspended in 1 ml of distilled H2O (54).  Samples were 344 
used immediately or freeze-dried and stored at -20°C until required. 345 
Screening of AHL extracts using CV026 induction and inhibition assays.  AHL extracts 346 
were tested using the C. violaceum CV026 biosensor strain using a well-diffusion assay (55).  347 
C. violaceum CV026 was grown in LB for 16 h at 30°C supplemented with kanamycin (50 348 
µg/ml).  This overnight culture was incorporated into LB agar plates (1.2%) by dilution 349 
(1:100).  In addition, induction plates also contained kanamycin (50 µg/ml) and inhibition 350 
plates both kanamycin and C10 AHL (50 nM) (17248, Sigma-Aldrich, Pool, UK).  A well (6 351 
mm) was made into the centre of each solidified agar plate.  Test AHL extracts (or controls) 352 
were then added to the well (adjusting with dH2O according to the dry weight of PAO1 353 
culture used).  The plates were then incubated at 30°C for 48 h.  Distances of violaceum 354 
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induction or inhibition as determined by the extent of purple colouration or zone of 355 
clearing, respectively, were then measured (mm).  356 
Cell-free culture supernatant.  Cultures of P. aeruginosa PAO1 were grown for 12, 18, 357 
24 and 30 h and prepared as described previously for growth curves. MH broth was selected 358 
as nutrient-limited media have been shown to enhance AHL production (9).  Cells were 359 
harvested (3900 g, 20 min, 4°C) and washed three times with ice cold 0.9% NaCl and dried 360 
at 80°C for 24 h.  In each case, differences in culture biomass (at OligoG CF-5/20 361 
concentrations >2%) from cell-free culture supernatants, used for the screening of AHLs and 362 
the extraction of all the virulence factors was corrected by normalisation according to dry 363 
weight.   364 
Quantitation of extracellular virulence factors.  Pyocyanin was extracted from the 365 
culture supernatant (700 µl) using chloroform in the ratio of 3:2 and re-extracted with 150 366 
µl of 0.2 M HCl and the absorbance read at 520 nm (17).  Rhamnolipids were extracted from 367 
culture supernatant with ethyl acetate in a 1:1 ratio, vortexed for 15 sec and centrifuged 368 
(10,000 g, 4°C, 5 min).  The upper layer was removed and ethyl acetate extraction repeated 369 
(x3) for each sample.  The combined upper layer was left to evaporate overnight.  Then 900 370 
µl of orcinol reagent (0.19% orcinol in 53% H2SO4) was added to the precipitate, and 371 
incubated at 80OC for 30 min, before reading the absorbance at 420 nm (51).  Protease 372 
activity was determined using 2% azocasein solution prepared in 50 mM phosphate buffer 373 
saline (PBS), pH 7.  The substrate and culture supernatant were incubated at 37°C in 1:1 374 
ratio for 1 h in a reaction volume of 400 µl.  The reaction was stopped by the addition of 500 375 
µl of 10% trichloroacetic acid and centrifuged at 8000 g for 5 min to remove residual 376 
azocasein.  The absorbance was read at 400 nm (17).  Elastase extraction employed, 200 µl 377 
elastin Congo red solution (5 mg/ml in 0.1 M Tris-HCl pH 8; 1 mM CaCl2) which was 378 
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incubated with 600 µl of cell-free, culture supernatant at 37°C for 3 h at 200 rpm.  The 379 
mixture was then centrifuged at 3000 g for 10 min and the absorbance read at 490 nm (17). 380 
High performance liquid chromatography triple quadrupole mass spectrometry 381 
(LC/MS).  AHLs were extracted as described above and freeze-dried until required.  Freeze 382 
dried samples were reconstituted in 200 µl of acetonitrile (ACN) with 0.1% acetic acid and 383 
7.2 ng/ml of the internal standard umbelliferone.  Samples were vortexed, centrifuged (16), 384 
(100 g, 4°C, 10 min) and supernatants filtered through 0.4 μm syringe filter (Phenomenex, 385 
UK) this was performed twice to increase metabolite extraction.  Samples were kept on ice 386 
throughout the extraction procedure prior to being run on the liquid chromatography Triple 387 
quadrupole mass spectrometer (LC-QQQ-MS).  Samples (5 μl) were loaded onto a C18 XDB 388 
Eclipse (1.8 µm, 4.6 x 50 mm) reverse phase column (Agilent Technologies, Palo Alto, USA).  389 
Samples were quantified using a 1200 series HPLC (Agilent Technologies, USA) coupled to a 390 
6410B enhanced sensitivity triple quadruple (QQQ) mass spectrometer (Agilent 391 
Technologies, USA).  For detection using positive ion mode, mobile phase A comprised of 5 392 
mM ammonium acetate in water modified with 0.1% acetic acid and B was acetonitrile 393 
containing 0.1% acetic acid.  The column was equilibrated in 2% B, before increasing in a 394 
linear fashion to 100% over 6 min; with 100% B being maintained for a further 2 min before 395 
column re-equilibration.  The column temperature was maintained at 35°C for the duration 396 
with a flow rate of 0.3 mL/min.  Source parameters were as follows: temperature, 350 °C, 397 
gas flow, 10 L/min; nebuliser, 35 psi; and capillary voltage, 4 kV.  Data were analysed using 398 
Agilent MassHunter QQQ Quantitative Analysis software (Version B.07.00).  Peak areas were 399 
normalized to the internal standard umbelliferone and concentrations calculated using 400 
standard concentration curves, offset against blank values (the average peak areas for the 401 
blanks).  402 
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RNA extraction for real time PCR (qPCR).  RNA was extracted from 24 h cultures of P. 403 
aeruginosa PAO1 grown at 37°C in MH broth +/- OligoG CF-5/20 (0.2, 2 and 10%).  Cultures 404 
were harvested (2000 g, 10 min), resuspended and adjusted to 1.0 x 108 CFU/ml in PBS and 405 
centrifuged (12,000 g, 2 min) and re-suspended in 0.5 ml RNA later and stored at -20°C until 406 
required.  Cells were pelleted (12,000 g, 2 min) and re-suspended with lysis buffer (RLT 407 
buffer, QIAgen, Crawley, UK) containing 1% (v/v) β-mercaptoethanol.  Cell debris was 408 
pelleted via centrifugation (12,000 g, 2 min), resulting supernatants were removed into 409 
fresh tubes, phenol:chloroform:isoamyl alcohol (25:24:1) was used to acquire total nucleic 410 
acid.  Total RNA was recovered after DNase I treatment using the RNeasy® Mini Kit 411 
(QIAGEN) according to the manufacturer’s instructions.  Gel electrophoresis was used to 412 
check the purity and integrity of the total RNA and RNA concentration was measured 413 
spectrophotometrically and an additional purity check using the absorbance ratio of 414 
260/280 nm (NanoVue, GE Healthcare, Little Chalfont, UK) and standardised to 300 ng/ml.  415 
Reverse transcription reactions for cDNA synthesis included total RNA (300 ng) template, 1 416 
μl of 50 μg/ml random primer and molecular grade water was added to give a final reaction 417 
volume of 10 μl.  RT-qPCR was performed in triplicate using NanoScript2 RT-Kit (primer 418 
design, UK) and a final annealing step of 5 min at 65°C, after which point the samples were 419 
cooled on ice.  Annealed samples were then added to the extension mix; 4 µl of 4 x 420 
nanoScript2 Buffer, 1 µl dNTP mix (10 mM), NanoScript2 enzyme at 1.5 µl (Primer Design, 421 
Southampton, UK), and 2.5 µl molecular grade water and a final volume of 20 µl was 422 
incubated at 25°C for 5 min and then at 42°C for 20 min.  423 
Real-time PCR (qPCR) for analysis of gene expression.  RT-qPCR for analysis of the 424 
expression of QS genes was carried out using the primers presented in Table 1.  Primer 425 
specificity was tested on genomic DNA.  RT-qPCR was performed in triplicate with three 426 
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replicate samples, using an ABI 7000 instrument (Life Technologies, UK).  Each reaction 427 
contained 2 μl cDNA, 12.5 μl (x2) of SYBR-Green PCR master mix (PrecisionPlus Mastermix; 428 
Primer Design, Southampton, UK), 10 mM of each primer and made up to 25 μl with highly 429 
purified water (Qiagen).  The thermal cycler profile comprised of initial denaturation at 95°C 430 
for 2 min, 40 cycles of denaturation at 95°C for 15 sec, primer annealing at 58°C (15 s), and 431 
extension at 72°C (30 s).  A final extension at 72°C for 2 min was performed, followed by 432 
cooling at 4°C.  A dissociation step at 60°C was used to generate a melting curve for 433 
verification of the amplified product.  After RT-qPCR, the threshold was adjusted according 434 
to the amplification curves of all evaluated genes.  Comparison between groups was made 435 
based on the cycle number at which both the target and the average of endogenous control 436 
genes (rpsL and proD) attained threshold cycle (Ct) fluorescence.  Analysis of relative gene 437 
expression was achieved according to the ΔΔCT method (56).   438 
eDNA determination of Pseudomonas aeruginosa PAO1 biofilms treated with OligoG 439 
CF-5/20 using a nucleic-acid specific cell impermeable fluorescent TOTO-1® stain.  The 440 
effect of OligoG on formation of 24 h P. aeruginosa PAO1 biofilms was tested.  For this, 441 
adjusted P. aeruginosa PAO1 cultures (107 CFU/ml) were diluted (1:0) in MH broth +/-OligoG 442 
CF-5/20 (0.5, 2, 6% w/v) and then incubated in Whatman 96-well glass-bottomed plates at 443 
37oC for 24 h with gentle agitation prior to staining.  The effect of OligoG on established 24 h 444 
biofilms was also tested to look at its effect on biofilm disruption.  For this, biofilms were 445 
grown without OligoG treatment using adjusted P. aeruginosa PAO1 cultures (107 CFU/ml), 446 
diluted (1:0) in MH broth.  After 24 h incubation, half the supernatant was removed and 447 
replaced with 100 μl fresh MH broth ± OligoG CF-5/20 (0.5, 2, 6% w/v) and the samples 448 
incubated for a further 24 h before staining.  After OligoG treatment, the supernatant was 449 
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removed and biofilms stained with TOTO®-1 (Thermofisher) for 25 mins.  Biofilm samples 450 
were imaged using a Leica TCS SP5 confocal system with a x63 lens.   451 
For fluorescence determination of eDNA, biofilms were homogenised by vigorous 452 
pipetting and the resulting supernatant filtered (0.2 µm).  Culture purity was confirmed by 453 
plating a loopful of supernatant onto non-selective blood agar.  Supernatants were stained 454 
with TOTO®-1 at room temperature for 35 min and fluorescence excitation/emission 455 
measured at ~514/533 nm on a FLUOstar Optima plate reader (BMG LABTECH) (47).  456 
Synthesis of N-decanoyl cyclopentylamide (C10-CPA).  Decanoyl chloride (1 mol eq; 457 
0.544 ml; 0.500 g; 2.6 mmol) was added dropwise to a stirring solution of cyclopentylamine 458 
(2 mol eq; 0.513 ml; 0.443 g; 5.2 mmol) in anhydrous dichloromethane (5 ml) under 459 
nitrogen atmosphere.  The reaction was stirred for 6 h and then the solvent evaporated 460 
under reduced pressure.  The residue was re-dissolved in 20 ml of diethyl ether and washed 461 
with water, 5% NaHCO3, 0.2 M HCl and saturated NaCl solution.  The organic layer was dried 462 
over MgSO4 and concentrated to furnish the N-cyclopentyldecanamide as a white solid and 463 
confirmed by hydrogen-1 nuclear magnetic resonance (H-NMR), carbon-13 NMR and 464 
electrospray ionization MS (30). 465 
Confocal laser scanning microscopy imaging of Pseudomonas aeruginosa biofilms 466 
treated with QS inhibitors.  Overnight cultures of P. aeruginosa PAO1 grown in tryptone 467 
soya broth (TSB) were adjusted to 107 CFU/ml and 10 µl of adjusted cultures added to 90 µl 468 
of MH broth in glass-bottomed 96 well plates.  Biofilms of P. aeruginosa PAO1 were grown 469 
(24 h) whilst being treated (rocking gently) with known AHL quorum sensing inhibitors of 470 
2(5H)-Furanone, (283754, Sigma-Aldrich, Pool, UK) at (1.25 µg ml-1 and 2.5 µg ml-1 (14.9 and 471 
29.7 µM respectively) (29, 30) and N-decanoyl cyclopentylamide (C10-CPA) at 100 and 250 472 
µM (30).  Untreated and OligoG-treated biofilms were used as controls.  Planktonic 473 
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cells/supernatant was removed before staining the biofilms with 6 % LIVE/DEAD® BacLight™ 474 
bacterial viability kit (Invitrogen, Paisley, UK) in PBS, incubating in the dark (10 min) and 475 
imaging with a Leica TCS SP5 confocal system using a x 63 lens. 476 
Circular dichroism (CD) spectroscopy.  To evaluate whether AHLs influence the 477 
conformation of OligoG CF-5/20, CD spectra were recorded on an Aviv 215 instrument (Aviv 478 
Biomedical Inc., Lakewood, NJ) from 260 to 200 nm, 1 nm band-width, using a 0.5-cm quartz 479 
cell at 37°C.  OligoG CF-5/20 was dissolved in 100 mM NaCl, 10 mM Tris-HCl, pH 7.5, at a 480 
concentration of 0.5 mg/ml and either C4-AHL or 3-oxo-C12-AHL (Sigma-Aldrich, Pool, UK, 481 
09014 and 09945) was added stepwise from 1mg/ml stock solutions. Buffer baselines and 482 
the intrinsic AHL spectra were subtracted, and spectra were corrected for dilution.  Data are 483 
presented as mean-residue-weight ellipticities [Θ]MRW assuming Mr = 194 g/mol for the 484 
OligoG CF-5/20 monosaccharides. 485 
 Statistical analysis.  Microsoft Excel was used to perform statistical analysis including 486 
one-way ANOVA using the Tukey-Kramer post-test and the minimum significant difference 487 
(MSD) was calculated using the Tukey-Kramer method (57).  P<0.05 was considered 488 
significant. 489 
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Table 1.  Genes and primers used for qPCR in this study.    
 
Gene 
Forward Primer  
(5' - 3') 
Reverse Primer  
(5' - 3') 
__Forward primer__ __Reverse primer__  Product 
size (bp)  
Reference 
BP GC TM BP GC TM 
lasI TGTTCAAGGAGCGCAAAGG ATGGCGAAACGGCTGAGTT 19 52.6 62.4 19 52.6 63 244 58 
lasR AGCGACCTTGGATTCTCGAAG CGAAGAACTCGTGCTGCTTTC 21 52.4 63 21 52.4 62.5 226 58 
rhlI TGCTCTCTGAATCGCTGGAA GTTTGCGGATGGTCGAACTG 20 50 59.1 20 55 59.83 154 58 
rhlR TTGCTGAGCGTGCTTTCC AGGATGATGGCGATTTCCC  19 52.6 62.6 19 52.6 62.1 228 58 
*rpsL CCTCGTACATCGGTGGTGAAG CCCTGCTTACGGTCTTTGACAC  21 57.1 62.8 22 54.5 63.1 148 59 
*proD GGGCGAAGAAGGAAATGGTC CAGGTGGCGTAGGTAGAGAA 20 55 63.1 20 55 58 178 60 
 
*Reference/endogenous control genes;  BP,primer length (basepairs);  GC, G-C content of primer; TM, melting temperature of primer 
FIG 1  Schematic diagram of the Pseudomonas aeruginosa virulence regulatory network showing the three major QS signalling pathways namely, the acyl 
homoserine lactone Las and Rhl operons and the 2-heptyl-3-hydroxy-4-quinolone Pseudomonas quinolone signal (PQS) operon. Differences in culture bio-
mass (at ≥2% OligoG) were corrected according to dry weight.
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FIG 2 Effect of OligoG CF-5/20 on the growth of P. aeruginosa PAO1 and the production of signalling molecules using the biosensor Chromobacterium
violaceum CV026. (A) Growth curves of P. aeruginosa PAO1 treated with OligoG CF-5/20 showing four specific sampling times (12, 18, 24 and 30 h) for AHL
extractions (arrows). Well-diffusion time-course assay detecting AHLs from (B) 24 h or (C) and (D) 12, 18, 24 and 30 h extracts of P. aeruginosa cultures treated
with OligoG (0.2, 2 and 10 %). (B) and (C) Induction (zone of colouration) or (B) and (D) Inhibition (zone of clearing) of violacein synthesis in C. violaceum CV026
showing changes in C4- and 3-oxo-C12-AHL production following OligoG treatment (n = 3 ± standard deviation; * P<0.05). MSD, minimum significant difference.
Differences in culture bio-mass (at ≥2% OligoG) were corrected according to dry weight.
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FIG 3  Method development for detection and quantification of acyl homoserone lactones (AHLs). (A) Structure of C4-AHL. (B) Structure of 3-oxo-C12-
AHL. (C) C4-AHL and 3-oxo-C12-AHL LC/Mass spectrometry peaks. (D) Initial time course showing LC/MS quantification of AHL concentrations (µg/L) 
from P. aeruginosa PAO1 grown in Mueller Hinton (MH) broth at different time points (18, 24 and 30 h). (n = 3 ± standard deviation; * P<0.05). Differences 
in culture bio-mass (at ≥2% OligoG) were corrected according to dry weight.
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FIG 4  Effect of OligoG CF-5/20 on AHL concentrations (µg/L) determined by LC/MS at different time points (12, 18, 24 and 30 h) in P. aeruginosa PAO1 
grown in Mueller Hinton (MH) broth ±OligoG (0.2, 2 and 10%).  A) C4-AHL.  B) 3-oxo-C12-AHL. (n = 3 ± standard deviation; * P<0.05). Differences in 
culture bio-mass (at ≥2% OligoG) were corrected according to dry weight.
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FIG 5  Extracellular virulence factor production by P. aeruginosa from 12, 18, 24 and 30 h cell free culture supernatants treated with OligoG CF-5/20 (0.2, 2 
and 10 %).  (A) pyocyanin. (B) rhamnolipids. (C) total protease. (D) elastase. (n = 4 ± standard deviation; * P<0.05). Differences in culture bio-mass (at 
≥2% OligoG) were corrected according to dry weight.
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FIG 6  Relative fold change in gene expression compared to untreated control using quantitative PCR of lasI/R, rhlI/R genes from 12, 18, 24 and 30 h cultures 
of P. aeruginosa PAO1 treated with OligoG CF-5/20  (0.2, 2 and 10%). (A) 12 h. (B) 18 h. (C) 24 h. (D) 30 h. (n = 3 ± standard deviation; * P<0.05). Differences 
in culture bio-mass (at ≥2% OligoG) were corrected according to dry weight.
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FIG 7  CLSM of Pseudomonas aeruginosa PAO1 biofilms treated with OIigoG CF-5/20 (0.5, 2 and 10%) and stained with nucleic acid specific TOTO-1 
(green). (A) Biofilm formation assay: Biofilms grown for 24 h in the presence of OligoG. (B) Biofilm disruption assay: 24 h established biofilms subsequently 
treated for 24 h with OligoG shown with corresponding fluorescence intensities in (C) and (D). (n = 3 ± standard deviation; * P<0.05). 
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FIG 8  Determination of eDNA concentration. Effect of OligoG (0.2, 2 and 10 %) on relative eDNA concentration in P. aeruginosa biofilms. Biofilm formation 
assay: biofilms grown for 24 h in the presence of OligoG and Biofilm disruption assay: 24 h established biofilms subsequently treated for 24 h with OligoG.
(n = 3 ± standard deviation; * P<0.05). Differences in culture bio-mass (at ≥2% OligoG) were corrected according to dry weight.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG S1  Confocal laser scanning microscopy of Pseudomonas aeruginosa PAO1 24 h biofilms 
treated with quorum sensing inhibitors.  (A) OligoG CF-5/20, 0 and 10%. (B) 2(5H)-furanone, 
1.25 µg/mL (14.9 µM). (C) N-decanoyl cyclopentylamide (C10-CPA), 100 µM, (n=3). 
 
 
  
  
 
 
 
 
 
 
FIG S2  Circular dichroism spectra showing the effect of OligoG (at a range of molar ratios) 
on homoserine lactones.  (A) C4-AHL and (B) 3-oxo-C12 AHL.  Insets show a time course 
recorded at 208nm after addition of AHLs at their maximum concentration. 
 
